Author(s)

Xijian Zhou, Jun Yang, Jinying Liang, Peng Li, Yuquan Wu, Xiaoqiang Fan, Xiangyong Li

.

The study was designed to evaluate the therapeutic and side effects of Bevacizumab plus FOLFIRI regimen as front-line therapy for Chinese patients with advanced colorectal cancer. A total of 15 previously untreated patients with advanced colorectal cancer received Bevacizumab plus FOLFIRI regimen as font-line therapy, in detail, irinotecan 180 mg/m² was given intravenously on day1, then calcium folinate (CF) 200 mg/m², F-fluorouracil (5-Fu) 400 mg/m² given in bolus immediately after CF, day 1 - 2; 5-Fu 600 mg/² given continuously after bolus for 22 hours on day1, day2; Bevacizumab was given intravenously at dosage of 5 mg/kg, on day-1. Therapeutic and side effects were evaluated at least after four cycles of treatment. The results showed that all the cases among the group were valid for response evaluation, with CR 0, PR 10, SD 3, and PD 2. The response rate is 66.7% and median time to progression (mTTP) was 10.6 months. The main toxicities were bone marrow suppression, nausea and vomiting, stomach pain and diarrhea; there was no chemotherapy-related death. The data suggested that the combination regimen with Bevacizumab plus FOLFIRI regimen was effective as front-line therapy for Chinese patients with advanced colorectal cancer, and the side effects were tolerable and manageable.

Bevacizumab, Chinese Patients, FOLFIRI Regimen, Front-Line Therapy, Colorectal Cancer

X. Zhou, J. Yang, J. Liang, P. Li, Y. Wu, X. Fan and X. Li, "Clinical Analysis of Bevacizumab Plus FOLFIRI Regimen as Front-Line Therapy for Chinese Patients with Advanced Colorectal Cancer," Journal of Cancer Therapy, Vol. 2 No. 4, 2011, pp. 470-474. doi: 10.4236/jct.2011.24063.